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Abstract. The first antibiotic, salvarsan, was deployed in 1910. In just over 100 15 
years antibiotics have drastically changed modern medicine and extended the 16 
average human lifespan by 23 years. The discovery of penicillin in 1928 started 17 
the golden age of natural product antibiotic discovery that peaked in the mid-18 
1950s. Since then, a gradual decline in antibiotic discovery and development and 19 
the evolution of drug resistance in many human pathogens has led to the current 20 
antimicrobial resistance crisis. Here we give an overview of the history of 21 
antibiotic discovery, the major classes of antibiotics and where they come from. 22 
We argue that the future of antibiotic discovery looks bright as new technologies 23 
such as genome mining and editing are deployed to discover new natural 24 
products with diverse bioactivities. We also report on the current state of 25 
antibiotic development, with 45 drugs currently going through the clinical trials 26 
pipeline, including several new classes with novel modes of action that are in 27 
phase 3 clinical trials. Overall, there are promising signs for antibiotic discovery, 28 
but changes in financial models are required to translate scientific advances into 29 
clinically approved antibiotics. 30 
 31 
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The development of antibiotics 33 
The introduction of antibiotics into clinical use was arguably the greatest medical 34 
breakthrough of the 20th century (Figure 1) [1]. As well as treating infectious 35 
diseases, antibiotics made many modern medical procedures possible, including 36 
cancer treatment, organ transplants and open-heart surgery. However, misuse of 37 
these valuable compounds has resulted in the rapid rise of antimicrobial 38 
resistance (AMR) with some infections now effectively untreatable [2]. The 39 
dangers of a post-antibiotic era has prompted policymakers to acknowledge this 40 
threat to human health and promise additional grant funding, which is gradually 41 
driving a resurgence of interest in antibiotic discovery and development [3]. The 42 
UK Government-commissioned O’Neill report predicted that without urgent 43 
action 10 million people a year will die from drug resistant infections by 2050 [4]. 44 
One of the key recommendations is to stimulate early stage drug discovery [4]. 45 
Given the relative lack of success in bringing effective synthetic antibiotics to the 46 
clinic [5], the best hope for developing a new generation of anti-infective drugs is 47 
to discover new microbial natural products (NPs) because these compounds are 48 
unrivalled in their chemical diversity and effectiveness as antibiotics [1]. 49 
Filamentous actinomycetes make 64% of the known NP antibiotic classes with 50 
the remainder made by other bacteria and fungi (Figure 2 and Table 1). Here we 51 
give a brief overview of the history of NP antibiotics and our prospects for 52 
discovering, developing and safeguarding a new generation of antibiotics. 53 
 54 
Table 1. All classes of clinically used antibiotics and their source. aClasses are 55 
defined by origin, structure and/or mechanism of action, which distinguishes 56 
between bacitracin, colistin and daptomycin, for example. bYear reported refers 57 
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to first report in literature. cThe European Medicines Agency recommended the 58 
withdrawal of fusafungine from the market in February 2016. dSalvarsan is no 59 
longer in clinical use. eSalicylic acids are found in nature, but this was not the 60 
source of this class of antibiotic. fCompound synthesis was inspired by natural 61 
antibiotic classes.  62 
 63 
A brief history of antibiotics 64 
The use of antibiotic-producing microbes to prevent disease stretches back 65 
millennia, with traditional poultices of mouldy bread being used to treat open 66 
wounds in Serbia, China, Greece and Egypt more than 2000 years ago. The 67 
Eber’s papyrus from 1550 BC is the oldest preserved medical document and 68 
includes mouldy bread and medicinal soil amongst its list of remedies [6]. An 69 
Anglo-Saxon recipe from 1000 years ago was also recently shown to kill MRSA 70 
(methicillin-resistant Staphylococcus aureus) [7]. However, the development of 71 
anti-infective drugs and the underlying concept of chemotherapy is widely 72 
accredited to Paul Ehrlich, who developed the synthetic arsenic-based pro-drugs 73 
salvarsan (salvation arsenic) and neo-salvarsan circa 100 years ago to treat 74 
Treponema pallidum, the causative agent of syphilis [8] (Figure 1). This 75 
represented one of the first systematic screens for drug discovery using a library 76 
of synthetic compounds and was inspired by Ehrlich’s work on dyes that 77 
specifically stained bacterial cells. Salvarsan was superseded by the sulfonamide 78 
prodrug Prontosil, discovered by Gerhard Domagk [9], a bacteriologist at Bayer 79 
who used the drug to save his daughter’s arm from amputation. Domagk and 80 
colleagues were effectively continuing the work of Paul Ehrlich because the sulfa 81 
drugs were inspired by azo dyes. Sulfonamides were the first truly effective, 82 
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broad spectrum antimicrobials in clinical use and are still in use today, but they 83 
were largely superseded by the discovery of penicillin, observed on a 84 
contaminated Petri dish by Alexander Fleming in 1928 [10]. Penicillin was later 85 
purified by Norman Heatley, Howard Florey, Ernst Chain and colleagues at 86 
Oxford, who were instrumental in the development of penicillin as a drug [11] 87 
(Figure 1). Dorothy Hodgkin solved the beta-lactam structure of penicillin in 88 
1945 [12]. resolving the famous debate between Robert Robinson, who favoured 89 
a thiazolidine-oxazolone structure, and several other notable chemists including 90 
Chain, Abrahams and Woodward, who believed it to be a beta-lactam [13]. This 91 
was an important breakthrough because it enabled the development of semi-92 
synthetic derivatives to bypass penicillin resistance. 93 
 Antibiosis between microbes was described well before the discovery of 94 
penicillin, including by Louis Pasteur, who proposed that microbes could secrete 95 
material to kill other bacteria [14]. The production of diffusible and heat-stable 96 
compounds by bacteria was being reported by the turn of the 20th century [15], 97 
and their utility in combatting infectious diseases had been explored. Arguably 98 
the first clinical use of an antibiotic was reported in the 1890s, where Emmerich 99 
and Löw used an extract of Pseudomonas aeruginosa (then known as Bacillus 100 
pycyaneus) to treat hundreds of patients and this extract, called pyocyanase, was 101 
used until the 1910s [16]. Pyocyanase was active towards multiple pathogens and 102 
incorrectly believed to be an enzyme. Instead, the active components of 103 
pyocyanase was likely to be a mixture of pyocyanin, a quorum sensing 104 
phenazine, and 2-alkyl-4-hydroxy-quinolones [17]. 105 
The discoveries of penicillin, tyrocidine and numerous reports of the 106 
production of antimicrobial compounds by microorganisms, led Selman 107 
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Waksman to start a systematic study of microbes as producers of antimicrobial 108 
compounds in the late 1930s. Waksman defined an antibiotic as ‘a compound 109 
made by a microbe to destroy other microbes’ and was instrumental in 110 
identifying soil-dwelling filamentous Actinomycetales (“actinomycetes”) as 111 
prolific producers of antimicrobial compounds [18]. Waksman discovered 112 
numerous antibiotics made by soil-dwelling actinomycetes, including neomycin 113 
and streptomycin, the first agent active against tuberculosis [18]. Waksman’s 114 
pioneering work identified the genus Streptomyces as prolific producers of NPs, 115 
or secondary metabolites, which are compounds not required for the normal 116 
growth, development, or reproduction of an organism in the laboratory. Many 117 
streptomycete NPs are active against bacteria, fungi, viruses, nematodes and 118 
insects and they have also been developed as anti-cancer and immunosuppressant 119 
drugs [19]. 120 
Waksman’s work initiated the Golden Age of antibiotic discovery from 121 
the 1940s to the 1960s. Most of these antibiotics are still in clinical use but their 122 
effectiveness has been eroded by the rise of AMR (Figure 1) [1]. In fact, the rapid 123 
and relatively easy discovery of multiple classes (and variations therein) of NP 124 
antibiotics during a relatively short period led to the excessive use of these drugs. 125 
This, coupled with a faltering antibiotic discovery pipeline from the 1970s 126 
onwards, has led to the current situation with few new antibiotics in the clinical 127 
trials pipeline  [1]. Hence, most antibiotics in clinical trials today are derivatives 128 
of known classes of NP or synthetic antibiotics rather than new classes of 129 
antibiotic (Table S1). Notably, this hiatus in antibiotic discovery aligns with a 130 
decline in the discovery of new NP families and the persistent rediscovery of 131 
known compounds in screening campaigns using microbial, and predominantly 132 
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actinomycete, fermentation extracts [1]. This, in part, led to a belief that all the 133 
‘low-hanging fruit’ had been harvested and resulted in most of major 134 
pharmaceutical and agrochemical companies shutting down their NP discovery 135 
departments.  136 
The divestment in NP research was accompanied by an investment in 137 
numerous high-throughput screening (HTS) programmes that aimed to discover 138 
new synthetic antibiotics, but these have proved unsuccessful. For example, 70 139 
HTS campaigns were conducted by GlaxoSmithKline (GSK) over 7 years using a 140 
collection of approximately 500,000 compounds, but this yielded very few leads, 141 
and no candidates for development [20]. Similarly, 65 HTS campaigns by 142 
AstraZeneca provided a few leads but none that were active against multi-drug 143 
resistant Gram-negative bacteria [21]. In recent years however, the discovery of 144 
new antibiotic-producing strains in under-explored environments combined with 145 
new tools for genome mining has reinvigorated the NP discovery field, e.g. [22-146 
24]. 147 
 148 
Why do microorganisms make antibiotics? 149 
Of all the antibiotics discovered between 1945 and 1978, 55% came from the 150 
genus Streptomyces (Figure 1) [25]. Several theories have been proposed to 151 
explain why soil microbes make so many bioactive NPs. The most likely 152 
explanation is that they have multiple functions, acting as chemical weapons to 153 
kill competitors in the soil either as protection (defensive) or predation 154 
(offensive), as signalling molecules to close relatives or to mediate interactions 155 
with eukaryotic hosts such as insects and plants [26-28]. This is consistent with 156 
evidence that Streptomyces species and other filamentous actinomycetes evolved 157 
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circa 440 million years ago, around the same time that plants first colonized land 158 
[25,29]. The filamentous growth of these bacteria would have provided an 159 
advantage in colonizing plant roots and we speculate that many of their NPs may 160 
have evolved or been co-opted to mediate these interactions [30]. 161 
 One of the more surprising discoveries to arise from microbial  genome 162 
sequencing is that many bacteria and fungi encode many more NP pathways than 163 
they actually make in the laboratory [31]. In general, at least three quarters of 164 
their potential NP capability is not switched on in vitro and this discovery has 165 
triggered huge efforts to develop tools and techniques to activate their “cryptic” 166 
BGCs in the hope of discovering novel chemical scaffolds with useful 167 
bioactivities [32-36]. Many studies have demonstrated that when activated or 168 
expressed heterologously, silent BGCs encode functional NP biosynthetic 169 
pathways [34]. This suggests that production of these compounds is triggered by 170 
environmental cues or by host organisms. Many invertebrates, including insects 171 
and marine sponges, form defensive and mutually beneficial symbioses 172 
(defensive mutualisms) with antibiotic-producing bacteria and it seems likely that 173 
most if not all land plants do the same [26,37-39]. Studying these bacteria in the 174 
context of their host using advanced techniques, such as stable isotope probing 175 
(SIP) and imaging mass spectrometry (IMS), may be one way to identify the 176 
thousands of novel compounds encoded by silent BGCs and to identify the NPs 177 
that are most important to their hosts  [40]. 178 
 179 
Prospects for natural product antibiotic discovery 180 
In the Golden Age of antibiotic discovery, new antibiotic classes were being 181 
discovered on an almost yearly basis by isolation of likely antibiotic-producing 182 
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organisms from soil samples. However, a finite number of NP classes from easy-183 
to-cultivate bacteria meant that compound rediscovery soon became a problem 184 
(Figure 1). More recently, the NP discovery field has been reinvigorated by the 185 
discovery of new antibiotic-producing strains in under-explored environments, 186 
combined with new tools for genome mining and heterologous pathway 187 
expression. 188 
 189 
Under-explored environments and ecological niches 190 
It is now clear that only a tiny fraction of the soils on earth have been sampled for 191 
antibiotic producers. Sampling more widely is likely to yield numerous new 192 
strains and BGCs, even from this traditional sampling environment. In addition, 193 
sampling under-explored environments that were inaccessible or unknown during 194 
the Golden Age is yielding new chemical structures [20,37,38]. These include the 195 
marine environment, where the marine actinomycete genus Salinospora has 196 
proven to be a source of multiple structurally novel NPs [41] such as 197 
salinosporamide A (Marizomib) , which has anticancer activity and is currently in 198 
Phase III clinical trials for the treatment of glioblastoma [42].  199 
 Mutualistic co-evolved bacteria might also be an excellent source of new 200 
NPs and studying these niches has the added advantage of uncovering interesting 201 
underlying biology and the opportunity to understand what these molecules 202 
actually do in nature [43,44]. Bacterial symbionts of marine invertebrates such as 203 
sponges are a rich source of novel NPs. For example, Candidatus Entotheonella 204 
species are uncultivated symbionts of the marine sponge Theonella swinhoei [45] 205 
and were shown to produce almost all the bioactive polyketides and modified 206 
peptides isolated from a chemotype of T. swinhoei.  207 
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 Sequencing of the human microbiome has also revealed many NP BGCs 208 
across Actinobacteria and other bacterial phyla, and the antibiotic lactocillin was 209 
identified from a human vaginal isolate [46]. Another antibacterial compound, 210 
lugdunin, was isolated from the commensal nasal bacterium Staphylococcus 211 
lugdunensis which prohibits colonization by Staphylococcus aureus and is active 212 
in animal models, with a high barrier to the development of resistance [47].  213 
 214 
Difficult to cultivate bacteria 215 
Genomic data suggesting the presence of novel BGCs in Clostridium bacteria 216 
prompted Hertweck and colleagues to investigate the antibiotic-producing 217 
potential of this genus, as no NPs had been characterised from clostridia. 218 
Clostridium cellulolyticum grown under standard laboratory conditions yielded 219 
no NPs, so fermentation was repeated with added aqueous soil extracts, as the 220 
bacterium had been isolated from decayed grass compost. This triggered the 221 
production of closthioamide, a new class of polythioamide antibiotic [48]. In 222 
another elegant example, the antibiotic humimycin was discovered by 223 
synthesising a putative peptide NP that was bioinformatically predicted from the 224 
genome of the actinomycete Rhodococcus equi, an opportunist human pathogen 225 
[23].  226 
 Other novel approaches have included the isolation of hard to culture 227 
bacteria from soil using diffusion chambers that allow for the growth of the pure 228 
bacterium in a complex natural environment [49]. This was miniaturised into an 229 
isolation chip (iChip) and used to culture 10,000 soil isolates that were otherwise 230 
intractable to laboratory fermentation. Extracts generated from these were then 231 
screened for antimicrobial activity and one resulted in the identification of the 232 
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antibacterial peptide teixobactin that is produced by Eleftheria terrae (Figure 4) 233 
[50]. These discoveries and recent metagenomics studies [51] highlight the 234 
continued relevance of traditional soil environments for antibiotic discovery . 235 
 The development of improved sampling methodologies for under-236 
explored environments and difficult to cultivate bacteria, combined with new 237 
genetic tools and technologies to activate interesting BGCs, is likely to lead to the 238 
discovery of thousands of new bioactive compounds over the next 20 years. It is 239 
highly probable that some fraction of these will form the basis of new anti-240 
infectives for clinical medicine, although this will require improved financial 241 
models to incentivise the development of new antibiotics.  242 
 243 
Prospects for clinical development. As of December 2018, there are 45 new 244 
antibiotic candidates in clinical trials for the US market (Table S1) [52]. Of these, 245 
28 belong to known NP classes while 17 are synthetic and comprise 12 classes, of 246 
which seven are new. The NP classes include 13 based on beta-lactams, which 247 
was the first class of NP antibiotic to be discovered back in 1928 (Fig. 1). Five of 248 
these are variant beta-lactams, two are hybrids (to a glycopeptide and a 249 
siderophore) and seven are combinations with beta-lactamase inhibitors (Table 250 
S1). There are five new tetracyclines, a class which was first described in 1945 251 
and introduced into the clinic in 1948, an aminoglycoside (1943), a distamycin 252 
(1962), a fusidane (1945), a macrolide (1952), a pleuromutilin (1950) and two 253 
polymyxins (1947). The fusidane (fusidic acid) is a fungal NP which is in Phase 254 
III trials in the United States, but it has already been used clinically elsewhere in 255 
the world. There are two new synthetic classes in Phase III clinical trials: 256 
ridinilazole, which specifically blocks cell division in C. difficile through a 257 
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mechanism that has not been revealed; and murepavedin, which has a novel 258 
mechanism of action, inhibiting LptD to block lipopolysaccharide transport to the 259 
outer membrane [53]. Murepavidin is effective against drug resistant 260 
Pseudomonas aeruginosa, one of the hardest pathogens to treat, particularly in 261 
patients with cystic fibrosis. It is also encouraging that four of the nine 262 
compounds in Phase II clinical trials represent novel classes, but this is still a 263 
modest number for the therapeutic area and is insufficient to combat multidrug-264 
resistant Gram-negative pathogens given the historically high attrition rate for 265 
compounds making it through clinical trials to clinical utility. AntibioticDB is an 266 
open access database that records candidate antibiotics, including antibiotics 267 
under pre-clinical development, those in clinical trials and discontinued drugs 268 
[54]. 269 
Unfortunately, most of the large pharmaceutical companies have left the 270 
field of NP discovery, and this work is now chiefly undertaken by academic labs 271 
and small to medium-sized companies. Only two of the 45 drugs currently in 272 
development belong to big pharmaceutical companies: the synthetic gepotacidin 273 
inhibits topoisomerase II through a mechanism distinct from that of quinolones 274 
and is being developed by GSK to treat gonorrhoea (phase 2) while Merck have a 275 
beta-lactam/lactamase combination in phase 3 clinical trials. The most notable 276 
NP antibiotic success in recent years was the introduction of Cubicin 277 
(daptomycin) onto the market by Cubist in 2003, and sales of this drug are now 278 
more than $1 billion a year. Cubicin is used by injection to treat vancomycin-279 
resistant Staphylococcus aureus (VRSA) and was discovered from Streptomyces 280 
roseosporus in 1987. In 2011, Cubist also purchased Optimer Pharmaceuticals, 281 
who secured clinical approval for Dificid (fidaxomicin, produced by the rare 282 
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actinomycete Dactylosporangium auranticus subsp. hamdenesis). This is the 283 
newest NP class to be introduced into the clinic, despite being discovered in 1975, 284 
before daptomycin [55]. Merck purchased Cubist in 2015 for $9.5B but have 285 
since closed the discovery arm of Cubist, which was heavily involved in NP 286 
discovery.  287 
In 2014 Sanofi and Fraunhofer announced the creation of a NP Centre of 288 
Excellence with the goal of identifying novel compounds to accelerate the 289 
discovery and development of new antibiotics. In 2016 Sanofi further announced 290 
a partnership with Warp Drive Bio to collaborate on the development of novel 291 
oncology therapies and antibiotics by using next generation sequencing and 292 
genome mining (on a massive scale) to identify new NPs but this ended in 2017. 293 
In 2018 Warp Drive Bio was effectively merged with Revolution Medicines, 294 
which is now focussed on oncology rather than anti-infectives, although Warp 295 
Drive Bio’s genome mining platform has recently been acquired by Ginkgo 296 
Bioworks. Roche have several strategic alliances, such as with Spero, which 297 
currently has two antibiotics in phase 1 and another in phase 3 clinical trials 298 
(Table S1). Several companies, including Genetech, are working on antibody-299 
antibiotic conjugates (AACs) [56]. Of the larger to mid-sized companies, Basilea 300 
is a major active player and focuses on the development of innovative antibiotics, 301 
antifungals and oncology drugs. In addition, there are innovative small to 302 
midsized companies in the antibacterial and antifungal discovery space including 303 
Tetraphase Pharma, which currently has two antibiotics in phase 1 clinical trials 304 
and recently had two more approved for use (Table S1). There is a heavy NP 305 
influence on all these companies, which appear to be using semisynthetic or total 306 
synthesis approaches within very specific areas of chemical space around known 307 
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drugs such as polyenes, macrolides and tetracyclines.  308 
Beyond the scientific difficulties associated with antibiotic discovery and 309 
development, there are a plethora of regulatory, economic, business and societal 310 
issues that must be addressed in order to protect and maximise the potential of 311 
our existing and future arsenal of clinical agents, while at the same time 312 
promoting the investment and culture changes required to invigorate antibiotics 313 
R&D to meet the challenges raised by AMR [57,58]. These have been analysed 314 
and recommendations made in several key reports including those by O’Neill and 315 
the Pew Trust [4,52]. Mossialos and colleagues comprehensively reviewed 47 316 
incentive strategies for the development of new antibiotics and concluded that a 317 
framework of multiple incentives and policies is required [59]. 318 
 319 
Summary and outlook. The rise in bacterial infections that are resistant to almost 320 
all known antibiotics is alarming, yet it is only in the last few years that 321 
governments have begun to tackle this problem seriously. This global wake-up 322 
call has stimulated a debate about how best to combat AMR and prompted the 323 
UK government to appoint an economist, Lord Jim O’Neill, to lead a strategic 324 
review [4]. The appointment of an economist highlighted the complexities of 325 
bringing to market a drug that, if functionally successful, will be dosed for only a 326 
short time. Combined with historically low prices, and the likelihood that any 327 
new antibiotic with a unique mode of action will most probably be restricted as a 328 
treatment of last resort, the economics of antibiotic R&D is a major disincentive 329 
to investment. To address these problems innovative solutions are required that 330 
provide a reimbursement model that delinks revenue from drug sales.  331 
 Scientifically, the identification of new chemical matter with the unique 332 
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physicochemical characteristics required for antibiotic discovery and 333 
development is a key challenge. NPs still represent the most likely source of new 334 
materials given the advances described in this review. Even the best-studied 335 
antibiotic producers, the streptomycetes, have been vastly under-sampled in terms 336 
of their capability, and there is confidence from the study of organisms from 337 
underexploited environments, ecological considerations, and genome sequencing 338 
that thousands of NP antibiotics await discovery across the bacterial kingdom. 339 
New tools and techniques such as CRISPR/Cas9-mediated genome editing are 340 
available to exploit these observations, and, although there is no universal 341 
strategy for the expression of silent BGCs, recent advances have led to the 342 
discovery of many new molecular structures with exceptional biological activities 343 
[34]. Further advances in this area will undoubtedly accelerate this rate of 344 
discovery further. 345 
Thus, governments are starting to act and there is much to be optimistic 346 
about, not least the fact that most of the NP antibiotics that have been discovered 347 
come from a small fraction of the microbes on Earth. With suitable global action, 348 
this should lead to a renewed antibiotic pipeline to combat AMR alongside other 349 
emergent technologies, such as vaccines, antibody-antibiotic conjugates, 350 
probiotics, phage therapy and rapid diagnostics [60]. 351 
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Figure 1. Timeline showing the decade new classes of antibiotic reached the 367 
clinic. The antibiotics are coloured per their source: green = actinomycetes, blue 368 
= other bacteria, purple = fungi and orange = synthetic. At the bottom of the 369 
timeline are key dates relating to antibiotic discovery and antimicrobial 370 
resistance, including the first reports of drug resistant strains methicillin-resistant 371 
Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), 372 
vancomycin-resistant Staphylococcus aureus (VRSA) and plasmid-borne colistin 373 
resistance in Enterobacteriaceae.  374 
 375 
Figure 2. Most clinically relevant classes of antibiotic are derived from 376 
natural products. 377 
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